|
| 36401732 | The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HRâ¿¿+â¿¿/HER2â¿¿-) advanced/metastatic breast cancer. | Breast Cancer Res Treat | 2023 |
| 36530475 | , a enhancer mutation, is an allele of . | | 2022 |
| 32247862 | Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level. | J Mol Diagn | 2020 |
| 30617129 | Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort. | Clinical Cancer Research | 2019 |
| 30171174 | Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers. | Molecular Cancer Research | 2019 |
| 30185228 | A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. | Breast Cancer Res | 2018 |
| 29936259 | Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. | J Mol Diagn | 2018 |
| 28798270 | A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors. | Oncologist | 2017 |
| 27603005 | A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). | Cancer | 2016 |
| 28721382 | The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. | npj Breast Cancer | 2016 |
| 26759240 | Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β. | Cancer Research | 2016 |
| 26787751 | Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2016 |
| 27174596 | Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. | Nature Communications | 2016 |
| 26951309 | Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. | Journal of Clinical Oncology | 2016 |
| 25370471 | First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. | Clin Cancer Res | 2015 |
| 24520381 | Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. | PLoS ONE | 2014 |
| 25338319 | Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples. | Breast Cancer Res Treat | 2014 |
| 24366379 | Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. | Oncogenesis | 2013 |
| 23284662 | Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel. | PLoS ONE | 2012 |
| 22402123 | ERK inhibition overcomes acquired resistance to MEK inhibitors. | Molecular Cancer Therapeutics | 2012 |
| 23136191 | Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. | Clinical Cancer Research | 2012 |
| 21868360 | miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. | Sci Signal | 2011 |
| 21673316 | TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. | Sci Signal | 2011 |
| 21998291 | GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. | Molecular Cancer Therapeutics | 2011 |
| 20838621 | Molecular biomarker analyses using circulating tumor cells. | PLoS One | 2010 |
| 19056674 | Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. | Molecular Cancer Therapeutics | 2008 |
| 17154430 | Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. | ChemMedChem | 2007 |
| 15208781 | A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. | Am J Hum Genet | 2004 |
| 10704412 | EGO-1 is related to RNA-directed RNA polymerase and functions in germ-line development and RNA interference in C. elegans. | Current Biology | 2000 |
| 10508845 | High-throughput isolation of Caenorhabditis elegans deletion mutants. | Genome Res | 1999 |
| 28565720 | DIVERGENCE IN SYMBIOTIC COMPATIBILITY IN A LEGUME-BRADYRHIZOBIUM MUTUALISM. | Evolution; international journal of organic evolution | 1996 |
| 28568881 | NONRANDOM GENOTYPIC ASSOCIATIONS IN A LEGUME-BRADYRHIZOBIUM MUTUALISM. | Evolution; international journal of organic evolution | 1996 |